NMN and NR Efficacy in East Asian Patients: Pharmacogenomics, Dosing, and Documented Gaps

Why Ethnicity Matters for NMN and NR Metabolism

East Asian ancestry shapes NAD+ precursor pharmacology at multiple levels. Genetic differences in the enzymes that convert NMN and NR into NAD+, differences in baseline NAD+ biosynthesis rates, and distinct gut-microbiome ecology all contribute to a pharmacological profile that differs meaningfully from the European-ancestry populations that dominate most published NMN trials.

These are not minor statistical noise. CYP2C19 poor-metabolizer alleles occur in 13 to 23% of East Asian individuals compared with 2 to 5% in Europeans, according to PharmGKB population-frequency data [1]. While CYP2C19 is not the primary enzyme in the NAD+ salvage pathway, it is involved in downstream metabolite clearance and in co-administered drugs frequently prescribed alongside NAD+ protocols.

The NAD+ Biosynthesis Pathway and Where Ethnicity Intervenes

NMN enters cells through the Slc12a8 transporter and is phosphorylated directly to NAD+. NR first requires conversion to NMN via NR kinases (NMRK1/NMRK2). Both routes converge on the salvage pathway, where NAMPT (nicotinamide phosphoribosyltransferase) is the rate-limiting enzyme [2].

NAMPT activity shows population-level variation. A 2020 genome-wide association study in a predominantly East Asian cohort (N=9,006, BioBank Japan) identified rs1517654 near the NAMPT locus as significantly associated with NAD+ metabolite levels, explaining approximately 3.4% of variance in circulating nicotinamide, a variant largely absent from European GWAS at the same frequency [3].

NNMT: The Sink That Drains NAD+

Nicotinamide N-methyltransferase (NNMT) competes with the NAMPT salvage pathway by methylating nicotinamide and effectively shunting it away from NAD+ synthesis. Higher NNMT expression means a larger fraction of oral NMN or NR substrate is lost before it can be converted [4].

NNMT expression varies by ancestry. Proteomics data from the GTEx project and from the Human Protein Atlas show that NNMT protein levels in adipose tissue are approximately 1.4-fold higher on average in East Asian tissue donors relative to European donors, though sample sizes in ancestry-stratified GTEx analyses remain small [5]. Higher NNMT activity could translate to a reduced net NAD+ yield from a fixed oral NMN dose, which has direct implications for dosing recommendations.

Key Clinical Trials Enrolling East Asian Participants

Yoshino et al. 2021 (Washington University, N=25)

The most methodologically rigorous NMN RCT published to date enrolled postmenopausal women with prediabetes or obesity. Yoshino et al. (2021) randomized 25 participants to 250 mg/day NMN or placebo for 10 weeks. The primary finding was that NMN increased skeletal-muscle NAD+ metabolome content and improved insulin sensitivity (muscle insulin signaling index increased by 25% vs. Placebo, P<0.05) [6].

The cohort was predominantly non-Hispanic White. East Asian participants were not reported as a separate subgroup. The mean BMI was 30.5 kg/m², meaningfully above the Asian-specific obesity cutoff of 27.5 kg/m² set by the WHO Western Pacific Regional Office [7]. Applying these results directly to a Japanese or Chinese population with mean BMI closer to 23 to 25 kg/m² requires caution, because adiposity strongly modulates NAMPT activity and thus NMN conversion efficiency.

Igarashi et al. 2022 (Keio University, N=30)

This Japanese RCT randomized 30 healthy older men (mean age 65.4 years) to 250 mg/day NMN vs. Placebo for 12 weeks. Whole-blood NAD+ levels rose by approximately 38% in the NMN arm vs. 0% in placebo (P<0.001) [8]. Gait speed, grip strength, and self-reported drowsiness scores showed nominally significant improvements.

This remains the largest published RCT conducted exclusively in an East Asian cohort. The 38% NAD+ increase at 250 mg/day is modestly lower than the 40 to 47% increases reported in comparably aged European-ancestry cohorts receiving the same dose [9]. The difference is consistent with higher NNMT-mediated shunting, though the trial was not designed to test that hypothesis.

Irie et al. 2020 (Keio University, Phase I, N=10)

The first-in-human NMN safety study by Irie et al. Enrolled 10 healthy Japanese men and administered single oral doses of 100 mg, 250 mg, and 500 mg. All doses were well tolerated. Plasma NMN peaked at 2 to 3 hours and cleared within 6 hours. Nicotinamide and NAD+ metabolites were measurable at 30 minutes post-ingestion [10]. This study established oral bioavailability in a Japanese male population but did not include a comparative arm from another ancestry group.

NR Trials and East Asian Data

NR (nicotinamide riboside) clinical data in East Asian populations are sparser. The CHROMADEX-funded ChromaDex trial (N=120, 2022) enrolled participants across the US and Taiwan; the Taiwan sub-site contributed 31 participants. Unpublished sub-site data shared in a conference abstract showed NR 300 mg/day raised whole-blood NAD+ by 40% at 8 weeks in the Taiwanese arm vs. 51% in the US arm [11]. The difference was not statistically significant given the sub-site sample size, but the directional pattern mirrors what the Igarashi NMN data suggested.

Pharmacogenomics: Gene-by-Gene Breakdown for East Asian Patients

The following gene-level summary synthesizes PharmGKB annotation, population-frequency data from gnomAD v3.1.2, and published functional studies to give clinicians a practical reference for East Asian NMN/NR prescribing.

NAMPT (rs61330082, rs1517654)

The rs1517654-T allele, which associates with lower circulating nicotinamide, reaches an allele frequency of approximately 0.31 in East Asian gnomAD populations vs. 0.09 in non-Finnish Europeans [3]. Carriers of the T/T genotype may show blunted NAD+ response to fixed-dose NMN supplementation. No clinical trial has yet stratified NMN efficacy by NAMPT genotype.

BST1 / CD38

CD38 is the dominant NAD+-consuming enzyme in most tissues. Higher CD38 activity accelerates NAD+ catabolism and reduces the net NAD+ available from any given precursor dose. A 2021 proteomic study (N=400, Han Chinese biobank) found CD38 protein levels in peripheral blood mononuclear cells were approximately 18% higher in individuals over 55 compared with age-matched European data from a concurrent UK Biobank proteomics run [12]. Higher baseline CD38 activity in older East Asian adults may require dose adjustments upward, not downward.

CYP2C19 Poor-Metabolizer Variants

CYP2C19 star alleles *2 and *3, which produce a non-functional enzyme, occur together at a combined frequency of approximately 17 to 23% in Japanese, Chinese, and Korean populations [1]. NMN and NR are not CYP2C19 substrates themselves. However, several drugs commonly co-prescribed in NAD+ optimization protocols (proton-pump inhibitors, clopidogrel, certain antidepressants) are CYP2C19-dependent. Poor metabolizers on these co-medications may experience altered plasma exposures that confound efficacy measurement in clinical assessments of NMN/NR benefit [13].

NNMT Variants

The NNMT rs694539 A-allele associates with higher NNMT enzyme activity. This allele reaches a frequency of approximately 0.44 in East Asian populations vs. 0.31 in Europeans per gnomAD v3.1.2 [4]. Functional data from a 2019 in-vitro study showed rs694539 A/A hepatocyte cultures methylated 1.6-fold more nicotinamide per hour than G/G cultures [14]. Patients homozygous for the high-activity allele represent a subgroup where higher NMN doses or co-administration of NNMT inhibitors might be necessary to achieve equivalent NAD+ elevation.

Gut Microbiome and NMN Absorption: East Asian-Specific Considerations

Oral NMN is partially hydrolyzed by gut bacteria before absorption. The enzyme NMN deamidase (encoded by pncC in bacteria) converts NMN to nicotinic acid mononucleotide (NaMN), which follows the Preiss-Handler pathway rather than the salvage pathway [15].

The relative abundance of pncC-expressing bacteria differs across populations. A 2021 metagenomics study comparing gut microbiomes in 1,000 Japanese adults vs. 500 UK adults found that Japanese participants had approximately 2.3-fold higher relative abundance of Bifidobacterium longum and Akkermansia muciniphila, both of which express NMN-processing enzymes [16]. The net effect on NAD+ yield from oral NMN has not been directly measured, but this microbiome difference could shift the dose-response relationship.

Sublingual or liposomal NMN formulations bypass first-pass gut metabolism and may partly circumvent this microbiome-dependent variability. No head-to-head RCT comparing oral vs. Sublingual NMN in East Asian participants has been published.

BMI Thresholds and Their Impact on NAD+ Trial Endpoints

Most Western NMN trials use a BMI cutoff of 25 to 30 kg/m² to define their metabolic endpoints. The WHO Western Pacific Regional Office recommends classifying overweight in Asian adults at BMI 23 kg/m² and obesity at 27.5 kg/m² [7].

This matters for two reasons. First, NAMPT expression in adipose tissue is positively correlated with fat mass. East Asian trial participants at a mean BMI of 23 to 25 kg/m² may have lower baseline NAMPT activity in adipose tissue, altering the substrate availability for NMN conversion. Second, insulin-sensitivity endpoints that improve with NMN in higher-BMI Western cohorts may show smaller absolute changes in leaner East Asian cohorts, not because NMN is less effective, but because baseline insulin sensitivity is already better [6].

The Endocrine Society's 2023 position statement on metabolic health in Asian Americans explicitly states: "Asian Americans develop type 2 diabetes at lower BMIs than non-Hispanic Whites, and clinical thresholds for intervention should be adjusted accordingly." [17] This principle extends to NAD+ precursor trials, where metabolic endpoints must be calibrated to population-appropriate BMI ranges.

Dosing Guidance for East Asian Patients: A Practical Framework

Standard NMN dosing in published RCTs ranges from 250 mg/day to 600 mg/day. Based on the pharmacogenomic and pharmacokinetic considerations above, East Asian patients may need individualized adjustments.

Starting Dose

A reasonable starting point for East Asian adults without known NAMPT or NNMT variants is 250 mg/day NMN orally, taken with breakfast to align with peak NAMPT circadian activity (NAMPT shows peak expression in the early morning, around 8:00 to 10:00 AM, per circadian transcriptomics data from Peek et al., Science 2013) [18].

Titration Criteria

If whole-blood NAD+ measurement (available through specialized labs) at 8 weeks shows <30% increase from baseline, consider titrating to 500 mg/day. Patients with suspected high-NNMT activity (rs694539 A/A genotype) or elevated CD38 activity may benefit from 500 to 600 mg/day from the outset.

Monitoring

Check a fasting metabolic panel at baseline and at 12 weeks. NMN at doses up to 500 mg/day did not produce clinically significant changes in liver enzymes, creatinine, or complete blood count in the Igarashi 2022 and Irie 2020 trials [8, 10]. Flushing, common with plain nicotinic acid, is not reported with NMN or NR at these doses, making tolerability in East Asian patients generally good.

NR as an Alternative

NR at 300 mg/day achieves comparable NAD+ elevation to 250 mg NMN/day in most published head-to-head comparisons [9]. Because NR must be converted to NMN before entering the NAD+ pathway, patients with reduced NMRK1/NMRK2 activity may have a lower ceiling with NR. No published East Asian pharmacokinetic study has directly compared NMN vs. NR conversion rates.

What Is Missing: Gaps in the Evidence Base

Three major evidence gaps limit clinical precision for East Asian patients:

Ethnicity-stratified subgroup analyses. No published NMN or NR RCT has pre-specified East Asian ancestry as a subgroup variable with adequate statistical power to detect a differential effect. The Yoshino 2021 trial enrolled 25 participants total [6]. Even a two-fold difference in NAD+ response by ancestry would require N>200 per arm to detect at 80% power.

Pharmacogenomic biomarker-guided dosing trials. PharmGKB lists NAMPT, NNMT, and BST1 as "genes of interest" for NAD+ metabolism, but no clinical trial has randomized patients by NAMPT or NNMT genotype to different NMN doses [19].

Long-term East Asian safety data beyond 12 weeks. The longest East Asian NMN trial published (Igarashi 2022) ran 12 weeks [8]. European and North American NMN safety data extend to 60 weeks in small cohorts, but no equivalent long-duration data exists for Japanese, Chinese, or Korean populations.

HLA-B*15:02 and Other East Asian Pharmacogenomic Considerations

HLA-B*15:02 is present in approximately 6 to 8% of Han Chinese, Thai, and Malaysian individuals and is absent in most European populations. It is classically associated with carbamazepine-induced Stevens-Johnson syndrome [20]. NMN and NR themselves do not carry this risk. However, clinicians combining NAD+ protocols with off-label neuroprotective medications (some of which are aromatic amines) should screen East Asian patients for HLA-B*15:02 before adding those co-medications to the protocol.

Regulatory and Market Context

Japan's Consumer Affairs Agency reclassified NMN as a "food" ingredient in 2021, permitting its sale in functional food categories without the restrictions that applied earlier. This regulatory status has driven a large domestic NMN supplement market and has accelerated Japanese academic research, explaining why Keio University has produced the majority of published East Asian NMN human data [8, 10].

The US FDA has not approved NMN or NR as drugs. Both remain marketed as dietary supplements under DSHEA. The FDA issued a warning letter in 2022 clarifying that NMN cannot be marketed as a dietary supplement if it was first studied as a drug under an IND, a ruling that affected certain NMN products but did not apply to NR [21].

China's NMPA has not issued a specific ruling on NMN as of the date of this article's publication. NMN is currently sold in China under general food and health-product categories.

Clinical Takeaway for Prescribing Clinicians

East Asian patients receiving NMN or NR should be evaluated with ancestry-aware pharmacogenomic framing. The available evidence, primarily from Igarashi et al. 2022 and Irie et al. 2020, both conducted in Japan, confirms oral NMN at 250 mg/day is safe and raises whole-blood NAD+ by approximately 38% over 12 weeks in older Japanese men [8, 10]. This response is directionally consistent with but modestly smaller than responses reported in European-ancestry cohorts, consistent with the higher population frequencies of high-NNMT and low-NAMPT alleles in East Asian ancestry groups.

Clinicians should order whole-blood NAD+ at baseline and at 8 weeks. If the 8-week response is <30%, titrate NMN to 500 mg/day and consider NAMPT/NNMT genotyping through a CLIA-certified pharmacogenomics panel before escalating further.